ATE509101T1 - Zinkfinger-bindungsdomänen für gnn - Google Patents

Zinkfinger-bindungsdomänen für gnn

Info

Publication number
ATE509101T1
ATE509101T1 AT06007722T AT06007722T ATE509101T1 AT E509101 T1 ATE509101 T1 AT E509101T1 AT 06007722 T AT06007722 T AT 06007722T AT 06007722 T AT06007722 T AT 06007722T AT E509101 T1 ATE509101 T1 AT E509101T1
Authority
AT
Austria
Prior art keywords
gnn
zinkfinger
binding domain
polypeptides
compositions
Prior art date
Application number
AT06007722T
Other languages
English (en)
Inventor
Carlos F Barbas
Original Assignee
Novartis Erfind Verwalt Gmbh
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh, Scripps Research Inst filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE509101T1 publication Critical patent/ATE509101T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06007722T 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn ATE509101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/173,941 US6140081A (en) 1998-10-16 1998-10-16 Zinc finger binding domains for GNN

Publications (1)

Publication Number Publication Date
ATE509101T1 true ATE509101T1 (de) 2011-05-15

Family

ID=22634148

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06007722T ATE509101T1 (de) 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn
AT99953825T ATE323720T1 (de) 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99953825T ATE323720T1 (de) 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn

Country Status (17)

Country Link
US (5) US6140081A (de)
EP (2) EP1715040B1 (de)
JP (2) JP2002527097A (de)
KR (1) KR100659922B1 (de)
CN (2) CN1896099A (de)
AT (2) ATE509101T1 (de)
AU (1) AU765630B2 (de)
BR (1) BR9914599A (de)
CA (1) CA2347025C (de)
DE (1) DE69930950T2 (de)
DK (1) DK1121381T3 (de)
ES (1) ES2263290T3 (de)
IL (3) IL142440A0 (de)
MX (1) MXPA01003755A (de)
NZ (4) NZ529585A (de)
WO (1) WO2000023464A2 (de)
ZA (1) ZA200102908B (de)

Families Citing this family (465)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285416B2 (en) * 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
AU746454B2 (en) 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
DE69932813D1 (de) 1998-03-17 2006-09-28 Gendaq Ltd Nukleinsäurebindungsproteine
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) * 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7329728B1 (en) * 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
HK1049515B (en) 1999-12-06 2006-01-13 Sangamo Biosciences Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
DE60143192D1 (de) * 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
ATE353361T1 (de) * 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
EP1276860B1 (de) 2000-04-28 2007-09-26 Sangamo Biosciences Inc. Datenbanken von regulatorischen sequenzen, methoden zu ihrer herstellung und verwendung
WO2001083819A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
WO2001084148A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
NZ523649A (en) * 2000-07-18 2005-02-25 Novartis Ag Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
EP1303608A2 (de) * 2000-07-21 2003-04-23 Syngenta Participations AG Code zur erkennung von zinkfingerdomänen und dessen verwendungen
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
AU2002225187A1 (en) * 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
CA2435394C (en) * 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
JP4309133B2 (ja) * 2001-02-21 2009-08-05 ノバルティス アクチエンゲゼルシャフト ヌクレオチド配列ａｎｎについての亜鉛フィンガー結合ドメイン
US7067617B2 (en) * 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
US7381813B2 (en) 2001-05-31 2008-06-03 Novartis Ag Nucleic acids encoding estrogen receptor ligand binding domain variants
WO2003016496A2 (en) * 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
AU2003251286B2 (en) * 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
CA2475276A1 (en) * 2002-02-07 2003-08-14 The Scripps Research Institute Zinc finger libraries
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
AU2003274404A1 (en) * 2002-06-11 2003-12-22 The Scripps Research Institute Artificial transcription factors
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
JP2006502748A (ja) * 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
EP1579005A4 (de) * 2002-11-15 2007-07-25 Sangamo Biosciences Inc Verfahren und zusammensetzungen zur analyse regulatorischer sequenzen
US8071285B1 (en) 2003-05-14 2011-12-06 Carl Henry Lawyer Zinc finger protein derivatives and methods of using same
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
JP4555292B2 (ja) 2003-08-08 2010-09-29 サンガモ バイオサイエンシズ インコーポレイテッド 標的化された切断及び組換えの方法及び組成物
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US7407776B2 (en) 2003-09-19 2008-08-05 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1737498A2 (de) * 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Zink-finger-proteine zur behandlung von neuropathischen schmerzen
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
EP1732945B1 (de) * 2004-04-08 2014-12-24 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur modulation der kardialen kontraktivität
EP2292274A1 (de) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Zusammensetzungen und Methoden zur Protein Herstellung
EP2166098B1 (de) 2004-10-05 2013-11-06 SunGene GmbH Konstitutive Expressionskassetten zur Regulation der Pflanzenexpression
EP1655364A3 (de) 2004-11-05 2006-08-02 BASF Plant Science GmbH Expressionskassetten zur bevorzugten Expression in Pflanzensamen
EP1662000B1 (de) 2004-11-25 2011-03-30 SunGene GmbH Expressionskassetten zur bevorzugten Expression in pflanzlichen Schliesszellen
EP1666599A3 (de) 2004-12-04 2006-07-12 SunGene GmbH Expressionskassetten zur bevorzugten Expression in Mesophyll- und/oder Epidermiszellen in Pflanzen
EP2163634A1 (de) 2004-12-08 2010-03-17 SunGene GmbH Expressionskassetten zur vaskularen, gewebebevorzugten Expression bei Pflanzen
EP1669456A3 (de) 2004-12-11 2006-07-12 SunGene GmbH Expressionskasseten für meristembevorzugte Expression in Pflanzen
EP1851318A2 (de) 2005-02-09 2007-11-07 BASF Plant Science GmbH Expressionskassette zur regulation der expression in einkeimblättrigen pflanzen
US20090031440A1 (en) 2005-02-26 2009-01-29 Basf Plant Science Gmbh Expression Cassettes for Seed-Preferential Expression in Plants
EP1869075B1 (de) * 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Antiangiogene methoden und zusammensetzungen
EP1882037A2 (de) 2005-05-10 2008-01-30 BASF Plant Science GmbH Expressionskassetten zur bevorzugten expression in pflanzensamen
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
WO2007019062A2 (en) * 2005-08-11 2007-02-15 The Scripps Research Institute Zinc finger binding domains for cnn
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
EP1963499A4 (de) * 2005-11-28 2009-04-08 Scripps Research Inst Zinkfinger-bindungsdomänen für tnn
US20070154989A1 (en) * 2006-01-03 2007-07-05 The Scripps Research Institute Zinc finger domains specifically binding agc
WO2007106603A2 (en) * 2006-01-06 2007-09-20 The Scripps Research Institute Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
WO2007136685A2 (en) * 2006-05-19 2007-11-29 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
ES2465996T3 (es) * 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
KR101439568B1 (ko) 2006-08-11 2014-09-12 다우 아그로사이언시즈 엘엘씨 아연 손가락 뉴클레아제-매개 상동 재조합
WO2008060510A2 (en) * 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
ES2586210T3 (es) 2006-12-14 2016-10-13 Sangamo Biosciences, Inc. Proteínas de dedo de zinc no canónicas optimizadas
CA2675926A1 (en) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
CA2684378C (en) 2007-04-26 2016-11-29 Sangamo Biosciences, Inc. Targeted integration into the ppp1r12c locus
US7919313B2 (en) 2007-07-12 2011-04-05 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
EP2188384B1 (de) * 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Schnelle in-vivo-identifizierung von biologisch aktiven nukleasen
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US8399218B2 (en) 2007-09-27 2013-03-19 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
BRPI0820653B1 (pt) 2007-12-03 2023-05-16 Syngenta Participations Ag Fitase isolada termotolerante e enzimaticamente suscetível, polinucleotídeo, cassete de expressão, vetor, célula hospedeira microbiana, método para preparar a referida fitase, preparação e ração animal
AU2009212247A1 (en) * 2008-02-08 2009-08-13 Sangamo Therapeutics, Inc. Treatment of chronic pain with zinc finger proteins
MX2010011511A (es) 2008-04-21 2011-06-09 Danziger Innovations Ltd Vectores de expresion viral de planta y uso de los mismos para generar variaciones genotipicas en genomas de plantas.
PL2274430T3 (pl) 2008-04-30 2017-09-29 Sanbio Inc Komórki regenerujące nerwy ze zmianami w metylacji DNA
CA2725773C (en) * 2008-05-28 2017-12-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
EP2294191B1 (de) 2008-06-10 2016-09-28 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur erzeugung von bax- und bak-mangel-zelllinien
AU2009283194B2 (en) 2008-08-22 2014-10-16 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
CN102264915B (zh) 2008-10-29 2014-04-16 桑格摩生物科学股份有限公司 失活谷氨酰胺合成酶基因表达的方法和组合物
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
AU2009322964B2 (en) 2008-12-04 2014-10-09 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
AR074783A1 (es) 2008-12-17 2011-02-09 Dow Agrosciences Llc Metodos y composiciones para expresar uno o mas productos de un acido nucleico exogeno integrado al locus zp15 de una celula vegetal
AU2010211057B2 (en) * 2009-02-04 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathies
WO2010107493A2 (en) * 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
CA2756833C (en) * 2009-04-09 2019-11-19 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
CA2769262C (en) * 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
ES2550202T3 (es) * 2009-08-03 2015-11-05 Recombinetics, Inc. Métodos y composiciones para la modificación dirigida de genes
EP3156504B1 (de) * 2009-08-11 2018-10-31 Sangamo Therapeutics, Inc. Für gezielte modifikation homozygote organismen
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
KR101813981B1 (ko) 2009-10-22 2018-01-04 다우 아그로사이언시즈 엘엘씨 지방산 생합성에 포함된 식물 유전자를 표적하는 조작된 징크 핑거 단백질
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
DE112010004582T5 (de) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh Optimierte Endonukleasen und Anwendungen davon
JP5902631B2 (ja) 2010-01-22 2016-04-13 ダウ アグロサイエンシィズ エルエルシー 標的化ゲノム変更
WO2011097036A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
PL2566972T3 (pl) 2010-05-03 2020-06-29 Sangamo Therapeutics, Inc. Kompozycje do wiązania modułów z motywem palca cynkowego
CA3157027A1 (en) 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
EP3511420B1 (de) 2010-09-27 2021-04-07 Sangamo Therapeutics, Inc. Zusammensetzungen zur hemmung des eindringens von viren in zellen
KR101930711B1 (ko) 2010-10-12 2018-12-19 더 칠드런스 호스피탈 오브 필라델피아 혈우병 ｂ의 치료를 위한 방법 및 조성물
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
MX2013010197A (es) 2011-03-18 2013-09-26 Basf Plant Science Co Gmbh Promotores para regular la expresion en plantas.
WO2012139045A1 (en) 2011-04-08 2012-10-11 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US9150847B2 (en) 2011-09-21 2015-10-06 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
WO2013059507A1 (en) 2011-10-20 2013-04-25 University Of Iowa Research Foundation N-demethyase genes and uses thereof
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
EP4218727A3 (de) 2012-01-27 2023-08-30 SanBio, Inc. Verfahren und zusammensetzungen zur modulation der angiogenese und vaskulogenese
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
WO2013158309A2 (en) 2012-04-18 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Non-disruptive gene targeting
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
JP6352250B2 (ja) 2012-05-02 2018-07-04 ダウ アグロサイエンシィズ エルエルシー リンゴ酸デヒドロゲナーゼの標的改変
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
US11120889B2 (en) 2012-05-09 2021-09-14 Georgia Tech Research Corporation Method for synthesizing a nuclease with reduced off-site cleavage
EP2861740A1 (de) 2012-06-15 2015-04-22 University of Iowa Research Foundation Koffeinreaktive promotoren und regulatorische gene
EP2872154B1 (de) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
CA2875618C (en) 2012-07-11 2021-04-27 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
DK2890780T3 (da) 2012-08-29 2020-09-21 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
KR102201867B1 (ko) 2012-09-04 2021-01-12 더 스크립스 리서치 인스티튜트 표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
HK1217732A1 (zh) 2012-09-07 2017-01-20 美国陶氏益农公司 Fad3性能基因座及相應的能夠誘導靶向斷裂的靶位點特異性結合蛋白
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
EP3763810A3 (de) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T-zell-modifizierende verbindungen und verwendungen davon
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
US20140173783A1 (en) 2012-12-13 2014-06-19 Dow Agrosciences Llc Precision gene targeting to a particular locus in maize
EP2958996B1 (de) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur verbesserung einer nuklease-vermittelten genunterbrechung
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP2975942B1 (de) 2013-03-21 2018-08-08 Sangamo Therapeutics, Inc. Gezielte disruption von t-zell rezeptorgenen mit manipulierten zinkfinger-proteinnukleasen
RU2723130C2 (ru) 2013-04-05 2020-06-08 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы и композиции для встраивания экзогенной последовательности в геном растений
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
EP3730615A3 (de) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
CA2920899C (en) 2013-08-28 2023-02-28 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
CN110713995B (zh) 2013-10-17 2023-08-01 桑格摩生物科学股份有限公司 用于核酸酶介导的基因组工程改造的递送方法和组合物
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
BR102014027442B1 (pt) 2013-11-04 2022-09-27 Dow Agrosciences Llc Molécula de ácido nucleico recombinante, uso de uma planta de milho, parte de planta de milho ou célula de planta de milho compreendendo a mesma e método para produzir uma célula vegetal transgênica compreendendo um dna de interesse
UY35814A (es) 2013-11-04 2015-05-29 Dow Agrosciences Llc ?lugares óptimos para la soja?.
MX358066B (es) 2013-11-04 2018-08-03 Dow Agrosciences Llc Óptimos loci de soya.
KR102269769B1 (ko) 2013-11-04 2021-06-28 코르테바 애그리사이언스 엘엘씨 최적 메이즈 유전자좌
AU2014346424B2 (en) 2013-11-11 2020-09-17 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
HUE056436T2 (hu) 2013-11-13 2022-02-28 Childrens Medical Center Nukleáz közvetítette génexpresszió-szabályozás
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
ES2813367T3 (es) 2013-12-09 2021-03-23 Sangamo Therapeutics Inc Métodos y composiciones para ingeniería genómica
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
HUE051232T2 (hu) 2014-02-03 2021-03-01 Sangamo Therapeutics Inc Béta-talasszémia kezelésére szolgáló eljárások és készítmények
AU2015218576B2 (en) 2014-02-24 2020-02-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
JP6594891B2 (ja) 2014-03-18 2019-10-23 サンガモ セラピューティクス， インコーポレイテッド ジンクフィンガータンパク質発現を調節するための方法および組成物
MX392639B (es) 2014-03-21 2025-03-24 Univ Leland Stanford Junior Vectores virales recombinantes para la integración de transgenes
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
CN106413760B (zh) 2014-05-08 2020-01-14 桑格摩生物科学股份有限公司 用于治疗亨廷顿病的方法和组合物
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3139909B1 (de) 2014-05-09 2025-01-01 Yale University Mit hyperverzweigtem polyglycerin beschichtete partikeln
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
EP3151846A4 (de) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur nukleasekonstruktion
EP3166964A1 (de) 2014-07-08 2017-05-17 Vib Vzw Mittel und verfahren zur steigerung des pflanzenertrags
FI3169778T3 (fi) 2014-07-14 2023-12-13 Univ Washington State Ituradan soluja ablatoiva nanos-geeninpoisto
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
US9757420B2 (en) 2014-07-25 2017-09-12 Sangamo Therapeutics, Inc. Gene editing for HIV gene therapy
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
HUE055583T2 (hu) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
HK1246690A1 (zh) 2015-01-21 2018-09-14 Sangamo Therapeutics, Inc. 用於鉴定高度特异性核酸酶的方法和组合物
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
WO2016159110A1 (ja) * 2015-03-31 2016-10-06 国立研究開発法人農業生物資源研究所 バイナリー遺伝子発現システム
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
BR112017021703B1 (pt) 2015-04-15 2023-11-28 Corteva Agriscience Llc Promotor de planta para expressão de transgene
EP3283633A2 (de) 2015-04-15 2018-02-21 Dow AgroSciences LLC Pflanzenpromoter zur transgenen expression
CN108026566A (zh) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
JP6873917B2 (ja) 2015-05-12 2021-05-19 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ介在性遺伝子発現調節
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
CN108024544B (zh) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
RU2018107842A (ru) 2015-08-06 2019-09-09 Дзе Кьюрейторз Оф Дзе Юниверсити Оф Миссури Устойчивые к патогенам животные, имеющие модифицированные гены cd163
TW201718862A (zh) 2015-09-22 2017-06-01 Dow Agrosciences Llc 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
TW201718861A (zh) 2015-09-22 2017-06-01 道禮責任有限公司 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
LT3352776T (lt) 2015-09-23 2025-07-10 Sangamo Therapeutics, Inc. Htt represoriai ir jų panaudojimas
EP4089175A1 (de) 2015-10-13 2022-11-16 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
CN108473997B (zh) 2015-10-22 2022-04-12 美国陶氏益农公司 用于转基因表达的植物启动子
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US20170121726A1 (en) 2015-11-04 2017-05-04 Dow Agrosciences Llc Plant promoter for transgene expression
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
WO2017095967A2 (en) 2015-11-30 2017-06-08 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
AU2016374253B2 (en) 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
ES2983043T3 (es) 2015-12-18 2024-10-21 Sangamo Therapeutics Inc Alteración dirigida del receptor de células T
AU2017207818B2 (en) 2016-01-15 2024-03-28 Regents Of The University Of Minnesota Methods and compositions for the treatment of neurologic disease
CN109069568B (zh) 2016-02-02 2023-07-07 桑格摩生物治疗股份有限公司 用于连接dna结合结构域和切割结构域的组合物
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
AU2017238512B2 (en) 2016-03-23 2022-12-08 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3443081A4 (de) 2016-04-13 2019-10-30 Duke University Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
US11410746B2 (en) 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
EP3475706B1 (de) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3484870B1 (de) 2016-07-13 2022-11-16 Vertex Pharmaceuticals Incorporated Verfahren, zusammensetzungen und kits zur erhöhung der genomeditierungseffizienz
EP4275747A3 (de) 2016-07-19 2024-01-24 Duke University Therapeutische anwendungen von cpf1-basierter genomeditierung
EP3490556A4 (de) 2016-07-27 2020-04-15 Case Western Reserve University Verbindungen und verfahren zur förderung der myelinisierung
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
BR112019003100A2 (pt) 2016-08-24 2019-07-09 Sangamo Therapeutics, Inc. regulação da expressão gênica usando nucleases manipuladas
IL300783B2 (en) 2016-08-24 2026-03-01 Sangamo Therapeutics Inc Engineered nucleases with target-specific zinc fingers
WO2018049009A2 (en) 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
US10400246B2 (en) 2016-10-03 2019-09-03 Dow Agrosciences Llc Plant promoter for transgene expression
WO2018067265A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
EP3519433A1 (de) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-spezifische bindungsmoleküle
EP3523422B1 (de) 2016-10-05 2024-12-25 FUJIFILM Cellular Dynamics, Inc. Erzeugung reifer linien aus induzierten pluripotenten stammzellen mit mecp2-unterbrechung
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
CN110022904B (zh) 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
US11766400B2 (en) 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
US11020492B2 (en) 2016-10-31 2021-06-01 Sangamo Therapeutics, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
EP3548616A4 (de) 2016-12-01 2020-05-13 Sangamo Therapeutics, Inc. Tau-modulatoren und verfahren und zusammensetzungen zur abgabe davon
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
CA3046199A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
CN119351474A (zh) 2017-02-22 2025-01-24 克里斯珀医疗股份公司 用于基因编辑的组合物和方法
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
KR20190140950A (ko) 2017-04-20 2019-12-20 오레곤 헬스 앤드 사이언스 유니버시티 인간 유전자 교정
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
KR20200026874A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 대장균 개량을 위한 htp 게놈 공학 플랫폼
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CN111278276B (zh) 2017-06-28 2023-05-26 美国陶氏益农公司 用于转基因表达的植物启动子
CA3071683A1 (en) 2017-08-08 2019-02-14 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
EP3692063A1 (de) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-spezifische bindungsmoleküle
US11225670B2 (en) 2017-10-30 2022-01-18 Corteva Agriscience Llc Plant promoter for transgene expression
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
BR112020008568A2 (pt) 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
WO2019094928A1 (en) 2017-11-10 2019-05-16 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
EP3728587A4 (de) 2017-12-18 2022-01-26 Syngenta Participations Ag Stellen zur gezielten insertion im maisgenom
KR20250048610A (ko) 2017-12-22 2025-04-09 페이트 세러퓨틱스, 인코포레이티드 향상된 면역 효과기 세포 및 이의 용도
AU2019209292B2 (en) 2018-01-17 2023-10-05 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
JP7391854B2 (ja) 2018-01-17 2023-12-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ－ｐｋ阻害剤
BR112020014140A2 (pt) 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated inibidores de dna-pk
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
CN111954540A (zh) 2018-02-08 2020-11-17 桑格摩生物治疗股份有限公司 工程化靶标特异性核酸酶
WO2019191495A1 (en) 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
EP3775238A1 (de) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Verfahren zur herstellung von zellen, die einen rekombinanten rezeptor exprimieren, und verwandte zusammensetzungen
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
EP3790629A1 (de) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Verfahren und zusammensetzungen zur behandlung von krebs
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
CA3102975A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
US11827892B2 (en) 2018-06-07 2023-11-28 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
WO2020028617A1 (en) 2018-08-01 2020-02-06 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
EP3841204A4 (de) 2018-08-23 2022-05-18 Sangamo Therapeutics, Inc. Modifizierte zielspezifische basiseditoren
EP3844287B1 (de) 2018-08-31 2024-05-22 Yale University Zusammensetzungen und verfahren zur verbesserung der oligonukleotidbasierten geneditierung
WO2020047353A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
AU2019344927A1 (en) 2018-09-18 2021-04-01 Sangamo Therapeutics, Inc. Programmed cell death 1 (PD1) specific nucleases
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
CN113226333A (zh) 2018-10-02 2021-08-06 桑格摩生物治疗股份有限公司 用于调控Tau蛋白的方法和组合物
US12583816B2 (en) 2018-10-18 2026-03-24 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020095248A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
US20220226375A1 (en) 2018-11-07 2022-07-21 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
WO2020095249A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
SG11202105480WA (en) 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
CA3121781A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
US12156877B1 (en) 2019-01-15 2024-12-03 The Regents Of The University Of California Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
US11857641B2 (en) 2019-02-06 2024-01-02 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
CN114174327A (zh) 2019-03-08 2022-03-11 黑曜石疗法公司 用于可调整调控的cd40l组合物和方法
US20200316116A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Method for the treatment of beta-thalassemia
PH12021552554A1 (en) 2019-04-23 2022-07-04 Sangamo Therapeutics Inc Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
KR20220026586A (ko) 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
CA3146967A1 (en) 2019-07-17 2021-01-21 Fate Therapeutics, Inc. Immune effector cell engineering and use thereof
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
US12485180B2 (en) 2019-08-30 2025-12-02 Yale University Compositions and methods for delivery of nucleic acids to cells
MX2022002763A (es) 2019-09-06 2022-04-06 Crispr Therapeutics Ag Linfocitos t modificados por ingenieria genetica que tienen persistencia mejorada en cultivo.
US20230002459A1 (en) 2019-10-02 2023-01-05 Sangamo Therapeutics, Inc. Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
US20230048224A1 (en) 2019-11-01 2023-02-16 Sangamo Therapeutics, Inc. Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
TW202132565A (zh) 2019-11-01 2021-09-01 美商聖加莫治療股份有限公司 Ｇｉｎ重組酶變異體
MX2022008415A (es) 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
BR112022019060A2 (pt) 2020-03-25 2022-11-29 Sana Biotechnology Inc Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
US12534744B2 (en) 2020-05-06 2026-01-27 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
MX2022015863A (es) 2020-06-19 2023-03-23 Fate Therapeutics Inc Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia.
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
JP7798855B2 (ja) 2020-07-16 2026-01-14 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に使用するためのカチオン性脂質
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
EP4501951A3 (de) 2020-08-25 2025-04-30 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
IL301014A (en) 2020-08-31 2023-05-01 Univ Yale Compositions and methods for delivery of nucleic acids to cells
AU2021347907A1 (en) 2020-09-23 2023-04-20 Crispr Therapeutics Ag Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
KR20230074519A (ko) 2020-09-25 2023-05-30 상가모 테라퓨틱스, 인코포레이티드 핵염기 편집을 위한 아연 핑거 융합 단백질
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
US20240000051A1 (en) 2020-11-16 2024-01-04 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
EP4277989A2 (de) 2021-01-12 2023-11-22 March Therapeutics, Inc. Kontextabhängige doppelsträngige dna-spezifische deaminasen und verwendungen davon
KR20230147644A (ko) * 2021-02-04 2023-10-23 뉴욕 유니버시티 천연 기능을 징발하기 위한 내인성 전사 인자에 조작된 징크 핑거의 원활한 통합
EP4305153A1 (de) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetisch veränderte t-zellen mit ptpn2-knockout mit verbesserter funktionalität und antitumoraktivität
KR20230158573A (ko) 2021-03-22 2023-11-20 주노 쎄러퓨티크스 인코퍼레이티드 바이러스 벡터 입자의 효력을 평가하는 방법
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
CA3214045A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
EP4334438A1 (de) 2021-05-05 2024-03-13 Fujifilm Cellular Dynamics, Inc. Verfahren und zusammensetzungen für mikroglia aus ipsc
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
BR112023024434A2 (pt) 2021-05-27 2024-02-20 Sana Biotechnology Inc Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
CN113429487B (zh) * 2021-06-21 2022-04-22 山东大学 一种能在水环境中去除抗生素耐药基因的人工合成蛋白
EP4370544A2 (de) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Veränderte expression von y-chromosom-gebundenen antigenen in hypoimmunogenen zellen
EP4377459A2 (de) 2021-07-30 2024-06-05 Tune Therapeutics, Inc. Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
JP2024531234A (ja) 2021-08-11 2024-08-29 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法のための遺伝子改変された初代細胞
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
KR20240055838A (ko) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 유도된 만능 줄기 세포 유래된 세포의 조성물 및 이의 사용 방법
US20230128917A1 (en) 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
AU2022371442A1 (en) 2021-10-21 2024-04-18 Vertex Pharmaceuticals Incorporated Hypoimmune cells
US20250313861A1 (en) 2021-10-22 2025-10-09 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
US20240409934A1 (en) 2021-10-25 2024-12-12 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
CA3235390A1 (en) 2021-10-29 2023-05-04 Deepika Rajesh Dopaminergic neurons comprising mutations and methods of use thereof
EP4426832A1 (de) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Genaue genomeditierung mit retrons
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023119201A2 (en) 2021-12-22 2023-06-29 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
US20250361528A1 (en) 2021-12-22 2025-11-27 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
JP2025508720A (ja) 2022-02-17 2025-04-10 サナ バイオテクノロジー，インコーポレイテッド 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照
TW202340457A (zh) 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
US12037616B2 (en) 2022-03-01 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
TW202403046A (zh) 2022-03-21 2024-01-16 瑞士商Ｃｒｉｓｐｒ治療公司 用於治療脂蛋白相關的疾病之方法及組成物
TW202346575A (zh) 2022-03-23 2023-12-01 瑞士商Ｃｒｉｓｐｒ治療公司 具有ｒｅｇｎａｓｅ－１及／或ｔｇｆｂｒｉｉ破壞的抗ｃｄ８３ ｃａｒ－ｔ細胞
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
US20230302423A1 (en) 2022-03-28 2023-09-28 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
JP7707304B2 (ja) 2022-04-08 2025-07-14 フェイト セラピューティクス，インコーポレイティド 腫瘍標的化のためのキメラ抗原受容体
CA3255335A1 (en) 2022-05-27 2023-11-30 President And Fellows Of Harvard College IMPROVED MITOCHONDRIAL BASIS EDITORS AND MITOCHONDRIAL DNA EDITING METHODS
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
CA3257650A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from genetically modified, multipotential stem cells with membrane IL-12 and their uses
EP4540387A2 (de) 2022-06-17 2025-04-23 CRISPR Therapeutics AG Auf lipidnanopartikeln (lnps) basierende okulare freisetzung
US20250381304A1 (en) 2022-06-21 2025-12-18 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
KR20250044484A (ko) 2022-06-24 2025-03-31 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
EP4554967A2 (de) 2022-07-12 2025-05-21 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur gezielten transkriptionsaktivierung
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
AU2023311477A1 (en) 2022-07-22 2025-01-30 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
CN120435557A (zh) 2022-08-19 2025-08-05 图恩疗法股份有限公司 通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
EP4615960A1 (de) 2022-11-09 2025-09-17 C3S2 GmbH Verfahren zur herstellung von manipulierten immunzellen
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
AU2023375625A1 (en) 2022-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
AU2023406926A1 (en) 2022-12-01 2025-06-26 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery
US20240269189A1 (en) 2022-12-19 2024-08-15 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
AU2023412431A1 (en) 2022-12-23 2025-08-07 Epigenic Therapeutics Pte. Ltd. Complex and use thereof
TW202440931A (zh) 2022-12-23 2024-10-16 大陸商益杰立科（上海）生物科技有限公司 融合物及其用途
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
CN120712355A (zh) 2023-02-15 2025-09-26 阿伯生物技术公司 用于抑制抑微管装配蛋白2（stmn2）转录物中的异常剪接的基因编辑方法
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
TW202444898A (zh) 2023-04-21 2024-11-16 美商凱特製藥公司 免疫排斥之風險降低的同種異體治療性細胞
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
TW202515898A (zh) 2023-06-30 2025-04-16 日商武田藥品工業股份有限公司 Ｈｔｔ抑制物及其用途
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
US20250027087A1 (en) 2023-07-21 2025-01-23 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025226122A1 (ko) * 2024-04-25 2025-10-30 (주)셀트리온 글루타민 합성효소 유전자를 불활성화시키는 방법 및 이를 이용한 목적 단백질의 생산 방법
WO2025224715A1 (en) 2024-04-26 2025-10-30 King Abdullah Univeristy Of Science And Technology Methods for improving precise genome modification and reducing unwanted mutations by crispr-cas editing
TW202605143A (zh) 2024-05-10 2026-02-01 美商奇諾治療有限公司 表現cd19嵌合抗原受體(car)之基因工程化t細胞及其用於同種異體細胞療法之用途
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026006832A1 (en) 2024-06-28 2026-01-02 University Of Connecticut Gene modulation for treating cancer
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317090A (en) * 1987-12-16 1994-05-31 Institut Pasteur Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human hepatocellular carcinoma, and which is a retinoic acid receptor
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US4990607A (en) * 1989-03-14 1991-02-05 The Rockefeller University Alteration of gene expression in plants
US5597693A (en) * 1989-03-17 1997-01-28 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
WO1991007509A1 (en) * 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
CA2090407A1 (en) * 1990-09-21 1992-03-22 Ronald M. Evans Functional antagonism between proto-oncoprotein c-jun and hormone receptors
US5324818A (en) * 1991-08-21 1994-06-28 The Regents Of The University Of Michigan Proteins useful in the regulation of κB-containing genes
US5243041A (en) * 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
EP0770129B1 (de) * 1994-01-18 2005-11-23 The Scripps Research Institute Derivate von zinkfingerproteinen und methoden
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2196419C (en) * 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5972664A (en) * 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
EP0905237A3 (de) * 1997-08-25 1999-12-22 Smithkline Beecham Corporation PIGR-2 ein Mitglied der Immunglobulingen-Superfamilie
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins

Also Published As

Publication number Publication date
NZ529583A (en) 2005-07-29
EP1121381A2 (de) 2001-08-08
KR100659922B1 (ko) 2006-12-21
NZ529584A (en) 2005-07-29
US7329541B2 (en) 2008-02-12
ZA200102908B (en) 2002-06-26
JP2010143936A (ja) 2010-07-01
CA2347025A1 (en) 2000-04-27
EP1715040A3 (de) 2007-09-12
DK1121381T3 (da) 2006-08-21
CA2347025C (en) 2012-01-03
US7101972B2 (en) 2006-09-05
US6610512B1 (en) 2003-08-26
US20100041028A1 (en) 2010-02-18
ATE323720T1 (de) 2006-05-15
DE69930950D1 (de) 2006-05-24
DE69930950T2 (de) 2006-12-14
MXPA01003755A (es) 2010-09-07
NZ511523A (en) 2004-01-30
BR9914599A (pt) 2001-11-13
AU765630B2 (en) 2003-09-25
WO2000023464A2 (en) 2000-04-27
NZ529585A (en) 2005-07-29
US20050148075A1 (en) 2005-07-07
US20060223757A1 (en) 2006-10-05
EP1715040B1 (de) 2011-05-11
KR20010080189A (ko) 2001-08-22
US6140081A (en) 2000-10-31
AU1037600A (en) 2000-05-08
IL199916A (en) 2011-06-30
ES2263290T3 (es) 2006-12-01
EP1121381B1 (de) 2006-04-19
CN1269958C (zh) 2006-08-16
WO2000023464A3 (en) 2000-11-16
JP2002527097A (ja) 2002-08-27
IL142440A0 (en) 2002-03-10
CN1330713A (zh) 2002-01-09
EP1715040A2 (de) 2006-10-25
CN1896099A (zh) 2007-01-17
IL142440A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
DE69930950D1 (de) Zinkfinger-bindungsdomänen für gnn
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
PE14199A1 (es) Agonistas de 5-ht1f
TR200101815T2 (tr) Sulu reaktif dolgu bileşimleri (I).
CY1111126T1 (el) Σκευασμα οφθαλμικων σταγονων που περιεχει κετοτιφαινη
ATE490311T1 (de) Mutanten der alpha-amylase
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
DE69813898D1 (de) Substituierte porphyrinen
PT1149092E (pt) 4- e 5-alciniloxindois e 4- e 5-alceniloxindois
DE69732309D1 (de) Primerzusammensetzungen für den Dentalbereich
ATE268750T1 (de) Proteintyrosinphosphatase inhibitoren
BR9907304B1 (pt) refratÁrio de alumina-magnÉsia-grafita.
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
DE69913965D1 (de) Zusammensetzung basierend auf wasserdispergierbaren polyurethanen
ATE441712T1 (de) Die nukleotidsequenz ann bindende zink-finger domänen
ATE117343T1 (de) Pigmentierte antikorrosive zusammensetzung zur beschichtung.
BR9711273A (pt) 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
IL135634A0 (en) 5-htif agonists
ATE364616T1 (de) Nucleinsäuremolekül, kit und verwendung
ATE230033T1 (de) Verwendung von primern für universelle fingerprint-analysen
FR2787340B3 (fr) Boitier pour des automates de jeu ou similaires
NO20003938L (no) Vann-dispergerbare flaksammensetninger
GR980100275A (el) Λιποφιλες σπειρανικες, 4,6-διαμινο-συμμετρικες τριαζινες και τα αντιστοιχα αλατα, τα ισομερη, στερεομερη και εναντιομερη τους, αναστολεις του ενζυμου της διυδροφολικης αναγωγασης

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties